BACKGROUND: Despite recent success in pharmacologic treatment of depression, the inability to predict individual treatment response remains a liability. This study replicates and extends findings relating pretreatment electroencephalographic (EEG) alpha to treatment outcomes for serotonergic medications. METHODS: Resting EEG (eyes-open and eyes-closed) was recorded from a 67-electrode montage in 41 unmedicated depressed patients and 41 healthy control subjects. Patients were tested before receiving antidepressants including a serotonergic mode of action (selective serotonin reuptake inhibitor [SSRI], serotonin and norepinephrine reuptake inhibitor, or SSRI plus norepinephrine and dopamine reuptake inhibitor). EEG was quantified by frequency principal components analysis of spectra derived from reference-free current source density (CSD) waveforms, which sharpens and simplifies EEG topographies, disentangles them from artifact, and yields measures that more closely represent underlying neuronal current generators. RESULTS: Patients who did not respond to treatment had significantly less alpha CSD compared with responders or healthy control subjects, localizable to well-defined posterior generators. The alpha difference between responders and nonresponders was greater for eyes-closed than eyes-open conditions and was present across alpha subbands. A classification criterion based on the median alpha for healthy control subjects showed good positive predictive value (93.3) and specificity (92.3). There was no evidence of differential value for predicting response to an SSRI alone or dual treatment targeting serotonergic plus other monoamine neurotransmitters. CONCLUSIONS: Findings confirm the value of EEG alpha amplitude as a viable predictor of antidepressant response and suggest that personalized treatments for depression may be identified using simple electrophysiologic CSD measures.
BACKGROUND: Despite recent success in pharmacologic treatment of depression, the inability to predict individual treatment response remains a liability. This study replicates and extends findings relating pretreatment electroencephalographic (EEG) alpha to treatment outcomes for serotonergic medications. METHODS: Resting EEG (eyes-open and eyes-closed) was recorded from a 67-electrode montage in 41 unmedicated depressedpatients and 41 healthy control subjects. Patients were tested before receiving antidepressants including a serotonergic mode of action (selective serotonin reuptake inhibitor [SSRI], serotonin and norepinephrine reuptake inhibitor, or SSRI plus norepinephrine and dopamine reuptake inhibitor). EEG was quantified by frequency principal components analysis of spectra derived from reference-free current source density (CSD) waveforms, which sharpens and simplifies EEG topographies, disentangles them from artifact, and yields measures that more closely represent underlying neuronal current generators. RESULTS:Patients who did not respond to treatment had significantly less alpha CSD compared with responders or healthy control subjects, localizable to well-defined posterior generators. The alpha difference between responders and nonresponders was greater for eyes-closed than eyes-open conditions and was present across alpha subbands. A classification criterion based on the median alpha for healthy control subjects showed good positive predictive value (93.3) and specificity (92.3). There was no evidence of differential value for predicting response to an SSRI alone or dual treatment targeting serotonergic plus other monoamine neurotransmitters. CONCLUSIONS: Findings confirm the value of EEG alpha amplitude as a viable predictor of antidepressant response and suggest that personalized treatments for depression may be identified using simple electrophysiologic CSD measures.
Authors: I A Cook; A F Leuchter; E Witte; M Abrams; S H Uijtdehaage; W Stubbeman; S Rosenberg-Thompson; C Anderson-Hanley; J J Dunkin Journal: Psychiatry Res Date: 1999-03-22 Impact factor: 3.222
Authors: Gerard E Bruder; Craig E Tenke; Virginia Warner; Yoko Nomura; Christian Grillon; Jeffrey Hille; Paul Leite; Myrna M Weissman Journal: Biol Psychiatry Date: 2005-02-15 Impact factor: 13.382
Authors: C L Larson; R J Davidson; H C Abercrombie; R T Ward; S M Schaefer; D C Jackson; J E Holden; S B Perlman Journal: Psychophysiology Date: 1998-03 Impact factor: 4.016
Authors: C E Tenke; J Kayser; L Miller; V Warner; P Wickramaratne; M M Weissman; G E Bruder Journal: Biol Psychol Date: 2013-08-30 Impact factor: 3.251
Authors: Ian A Cook; Aimee M Hunter; Marissa M Caudill; Michelle J Abrams; Andrew F Leuchter Journal: J Psychiatr Res Date: 2020-02-26 Impact factor: 4.791
Authors: Jürgen Kayser; Craig E Tenke; Christopher J Kroppmann; Daniel M Alschuler; Shiva Fekri; Shelly Ben-David; Cheryl M Corcoran; Gerard E Bruder Journal: Int J Psychophysiol Date: 2013-12-13 Impact factor: 2.997
Authors: Craig E Tenke; Jürgen Kayser; Pia Pechtel; Christian A Webb; Daniel G Dillon; Franziska Goer; Laura Murray; Patricia Deldin; Benji T Kurian; Patrick J McGrath; Ramin Parsey; Madhukar Trivedi; Maurizio Fava; Myrna M Weissman; Melvin McInnis; Karen Abraham; Jorge E Alvarenga; Daniel M Alschuler; Crystal Cooper; Diego A Pizzagalli; Gerard E Bruder Journal: Psychophysiology Date: 2017-01 Impact factor: 4.016
Authors: Craig E Tenke; Jürgen Kayser; Jorge E Alvarenga; Karen S Abraham; Virginia Warner; Ardesheer Talati; Myrna M Weissman; Gerard E Bruder Journal: Clin Neurophysiol Date: 2018-04-16 Impact factor: 3.708
Authors: Alik S Widge; M Taha Bilge; Rebecca Montana; Weilynn Chang; Carolyn I Rodriguez; Thilo Deckersbach; Linda L Carpenter; Ned H Kalin; Charles B Nemeroff Journal: Am J Psychiatry Date: 2018-10-03 Impact factor: 18.112